Tinavi Medical TechnologiesLtd Salute del bilancio

Salute finanziaria criteri di controllo 4/6

Tinavi Medical TechnologiesLtd ha un patrimonio netto totale di CN¥1.2B e un debito totale di CN¥225.0M, che porta il suo rapporto debito/patrimonio netto a 18.2%. Le sue attività totali e le sue passività totali sono rispettivamente CN¥1.6B e CN¥349.7M.

Informazioni chiave

18.6%

Rapporto debito/patrimonio netto

CN¥224.32m

Debito

Indice di copertura degli interessi	n/a
Contanti	CN¥222.03m
Patrimonio netto	CN¥1.20b
Totale passività	CN¥338.02m
Totale attività	CN¥1.54b

Aggiornamenti recenti sulla salute finanziaria

Is Tinavi Medical TechnologiesLtd (SHSE:688277) A Risky Investment?

Jun 14

Health Check: How Prudently Does Tinavi Medical TechnologiesLtd (SHSE:688277) Use Debt?

Feb 27

Recent updates

What Tinavi Medical Technologies Co.,Ltd.'s (SHSE:688277) 60% Share Price Gain Is Not Telling You

Oct 09

Is Tinavi Medical TechnologiesLtd (SHSE:688277) A Risky Investment?

Jun 14

More Unpleasant Surprises Could Be In Store For Tinavi Medical Technologies Co.,Ltd.'s (SHSE:688277) Shares After Tumbling 26%

Apr 21

There's Reason For Concern Over Tinavi Medical Technologies Co.,Ltd.'s (SHSE:688277) Massive 25% Price Jump

Mar 06

Health Check: How Prudently Does Tinavi Medical TechnologiesLtd (SHSE:688277) Use Debt?

Feb 27

Analisi della posizione finanziaria

Passività a breve termine: Le attività a breve termine ( CN¥453.2M ) di 688277 superano le sue passività a breve termine ( CN¥140.6M ).

Passività a lungo termine: Le attività a breve termine di 688277 ( CN¥453.2M ) superano le sue passività a lungo termine ( CN¥209.1M ).

Storia e analisi del rapporto debito/patrimonio netto

Livello di debito: Il rapporto debito netto/patrimonio netto ( 0.6% ) di 688277 è considerato soddisfacente.

Riduzione del debito: Il rapporto debito/patrimonio netto di 688277 è aumentato da 0% a 18.2% negli ultimi 5 anni.

Bilancio

Analisi della pista di contanti

Per le società che in passato sono state mediamente in perdita, valutiamo se hanno almeno un anno di liquidità.

Pista di liquidità stabile: 688277 ha una pista di cassa sufficiente per più di un anno in base al suo attuale flusso di cassa libero.

Previsione Cash Runway: 688277 ha meno di un anno di liquidità disponibile se il flusso di cassa libero continua a ridursi ai tassi storici del 36.2 % ogni anno

Tinavi Medical TechnologiesLtd Salute del bilancio

Salute finanziaria criteri di controllo 4/6

Informazioni chiave

Aggiornamenti recenti sulla salute finanziaria

Is Tinavi Medical TechnologiesLtd (SHSE:688277) A Risky Investment?

Health Check: How Prudently Does Tinavi Medical TechnologiesLtd (SHSE:688277) Use Debt?

Recent updates

What Tinavi Medical Technologies Co.,Ltd.'s (SHSE:688277) 60% Share Price Gain Is Not Telling You

New minor risk - Share price stability

Tinavi Medical Technologies Co.,Ltd. to Report Q3, 2024 Results on Oct 30, 2024

Second quarter 2024 earnings released: CN¥0.085 loss per share (vs CN¥0.093 loss in 2Q 2023)

Tinavi Medical Technologies Co.,Ltd. to Report First Half, 2024 Results on Aug 28, 2024

Is Tinavi Medical TechnologiesLtd (SHSE:688277) A Risky Investment?

Tinavi Medical Technologies Co.,Ltd., Annual General Meeting, Jun 27, 2024

Full year 2023 earnings released: CN¥0.35 loss per share (vs CN¥0.26 loss in FY 2022)

More Unpleasant Surprises Could Be In Store For Tinavi Medical Technologies Co.,Ltd.'s (SHSE:688277) Shares After Tumbling 26%

Tinavi Medical Technologies Co.,Ltd. to Report Q1, 2024 Results on Apr 27, 2024

There's Reason For Concern Over Tinavi Medical Technologies Co.,Ltd.'s (SHSE:688277) Massive 25% Price Jump

Full year 2023 earnings released: CN¥0.36 loss per share (vs CN¥0.26 loss in FY 2022)

Health Check: How Prudently Does Tinavi Medical TechnologiesLtd (SHSE:688277) Use Debt?

Third quarter 2023 earnings released: CN¥0.082 loss per share (vs CN¥0.088 loss in 3Q 2022)

Second quarter 2023 earnings released: CN¥0.093 loss per share (vs CN¥0.039 loss in 2Q 2022)

TINAVI Medical Technologies Co., Ltd. to Report Q2, 2023 Results on Aug 23, 2023

Full year 2022 earnings released: CN¥0.26 loss per share (vs CN¥0.19 loss in FY 2021)

Full year 2022 earnings released: CN¥0.27 loss per share (vs CN¥0.19 loss in FY 2021)

Beijing Huilin Oriental Technology Partnership Enterprise (Limited Partnership) and Wang Binbin entered into an agreement to acquire 12% stake in Beijing Shuimu Dongfang Medical Robotics Technology Innovation Center Co., Ltd. from TINAVI Medical Technologies Co., Ltd. (SHSE:688277).

Less than half of directors are independent

Third quarter 2022 earnings released: CN¥0.088 loss per share (vs CN¥0.06 loss in 3Q 2021)

Second quarter 2022 earnings released: CN¥0.039 loss per share (vs CN¥0.031 loss in 2Q 2021)

First quarter 2022 earnings released: CN¥0.07 loss per share (vs CN¥0.06 loss in 1Q 2021)

Full year 2021 earnings: Revenues and EPS in line with analyst expectations

Third quarter 2021 earnings released: CN¥0.06 loss per share (vs CN¥0.04 loss in 3Q 2020)

Second quarter 2021 earnings released: CN¥0.031 loss per share (vs CN¥0.049 loss in 2Q 2020)

TINAVI Medical Technologies Co., Ltd. announced that it expects to receive CNY 1.34 billion in funding

First quarter 2021 earnings released: CN¥0.06 loss per share (vs CN¥0.04 loss in 1Q 2020)

Full year 2020 earnings released: CN¥0.14 loss per share (vs CN¥0.08 loss in FY 2019)

New 90-day low: CN¥34.82

New 90-day low: CN¥45.92

New 90-day low: CN¥55.62

TINAVI Medical Technologies Co., Ltd. to Report First Half, 2020 Results on Aug 25, 2020

Analisi della posizione finanziaria

Storia e analisi del rapporto debito/patrimonio netto

Bilancio

Analisi della pista di contanti

Scoprire le aziende sane